KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2025)

Adaptive Biotechnologies' Cash from Financing Activities history spans 8 years, with the latest figure at $21.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 16953.54% year-over-year to $21.7 million; the TTM value through Dec 2025 reached $30.4 million, up 12515.35%, while the annual FY2025 figure was $30.4 million, 12515.35% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $21.7 million at Adaptive Biotechnologies, up from $1.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $125.5 million in Q3 2022 and bottomed at $6000.0 in Q4 2022.
  • The 5-year median for Cash from Financing Activities is $1.6 million (2025), against an average of $9.6 million.
  • The largest annual shift saw Cash from Financing Activities crashed 99.99% in 2023 before it surged 16953.54% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $3.3 million in 2021, then plummeted by 99.82% to $6000.0 in 2022, then soared by 1350.0% to $87000.0 in 2023, then skyrocketed by 45.98% to $127000.0 in 2024, then soared by 16953.54% to $21.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Cash from Financing Activities are $21.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.6 million (Q2 2025).